Halozyme Therapeutics (NASDAQ:HALO) Issues Earnings Results

Halozyme Therapeutics (NASDAQ:HALO) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16), FiscalAI reports. The business had revenue of $451.77 million for the quarter, compared to the consensus estimate of $446.13 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.Halozyme Therapeutics’s revenue for the quarter was up 51.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.26 earnings per share.

Here are the key takeaways from Halozyme Therapeutics’ conference call:

• Halozyme reported a record $1.4 billion in 2025 revenue (up 38%) and $868M in royalty revenue (up 52%), driven mainly by ENHANZE-enabled blockbusters DARZALEX SC, Phesgo and VYVGART Hytrulo.
• The company broadened its subcutaneous delivery portfolio by acquiring Elektrofi’s Hypercon and Surf Bio’s hyperconcentration technologies (IP into the mid‑2040s), positioning Halozyme as a one‑stop shop and targeting ~36 combined commercial/development products by 2028.
• Preclinical data indicate ENHANZE may enable safe subcutaneous delivery of antibody‑drug conjugates with much lower Cmax and similar or higher overall exposure, a finding that could materially expand ENHANZE’s addressable modalities if confirmed clinically.
• Management reiterated strong 2026 guidance (total revenue $1.71–$1.81B; royalty revenue $1.13–$1.17B; non‑GAAP EPS $7.75–$8.25) and highlighted balance‑sheet moves (new convertible notes, repurchases, larger revolver) with a plan to delever below 1x net debt/EBITDA by end‑2026.
• Legal and IP risk remains — an IPR involving Alteogen and an active district‑court infringement case (involving Merck) are ongoing, with discovery permitted, creating potential litigation uncertainty for the company.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded up $1.04 on Tuesday, reaching $80.48. 2,101,709 shares of the company’s stock were exchanged, compared to its average volume of 1,771,836. The company has a fifty day moving average of $71.55 and a 200-day moving average of $70.25. Halozyme Therapeutics has a twelve month low of $47.50 and a twelve month high of $82.22. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. The company has a market capitalization of $9.46 billion, a price-to-earnings ratio of 14.93, a PEG ratio of 0.33 and a beta of 0.97.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Reported record full‑year 2025 total revenue of $1.397B and reiterated 2026 guidance with strong growth ranges (2026 total revenue $1.71–$1.81B; adjusted EBITDA $1.125–$1.205B; non‑GAAP EPS $7.75–$8.25), which supports revenue visibility and margin expansion expectations. PR Newswire Release
• Positive Sentiment: Fourth‑quarter revenue came in at roughly $452M, up ~52% year‑over‑year and slightly above consensus, underscoring continued strength in the ENHANZE royalties and partner revenue streams. Quiver Quant
• Neutral Sentiment: Street sentiment remains broadly constructive (consensus “Moderate Buy” / median price target ~$84.5) though analyst targets vary widely — a mixed analyst backdrop that can mute extreme moves. Quiver Quant (analyst notes)
• Neutral Sentiment: Educational/momentum coverage and retrospectives (e.g., Zacks, MSN/Benzinga previews) may attract momentum and retail interest but are less likely to move the stock materially versus the company’s fundamentals and guidance. Zacks Momentum Piece
• Negative Sentiment: Reported EPS missed consensus (quarterly EPS reported at a loss versus higher analyst expectations) and the company recorded a larger operating and net loss in the quarter, which triggered near‑term selling pressure after the release. MarketBeat Earnings Summary
• Negative Sentiment: Quiver highlights a significant year‑over‑year rise in operating loss and liabilities, plus heavy insider stock sales (multiple executives sold shares recently), which can concern investors about near‑term dilution or sentiment. Quiver Quant (financials & insider activity)

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $76.12, for a total transaction of $1,522,400.00. Following the sale, the chief executive officer owned 708,719 shares in the company, valued at $53,947,690.28. This represents a 2.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $70.25, for a total transaction of $140,500.00. Following the transaction, the director directly owned 40,123 shares in the company, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 49,398 shares of company stock valued at $3,650,592 over the last 90 days. Corporate insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Large investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its holdings in shares of Halozyme Therapeutics by 19.6% in the 4th quarter. AQR Capital Management LLC now owns 1,158,359 shares of the biopharmaceutical company’s stock worth $77,958,000 after buying an additional 189,848 shares during the last quarter. Abel Hall LLC boosted its holdings in shares of Halozyme Therapeutics by 4.2% in the fourth quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 129 shares during the period. EFG International AG bought a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at $3,467,000. Laird Norton Wetherby Trust Company LLC purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter worth about $572,000. Finally, Amundi lifted its stake in Halozyme Therapeutics by 124.4% in the 4th quarter. Amundi now owns 20,148 shares of the biopharmaceutical company’s stock worth $1,356,000 after purchasing an additional 11,170 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on HALO. Citizens Jmp boosted their price objective on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research report on Tuesday, November 4th. The Goldman Sachs Group restated a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Weiss Ratings raised Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, February 10th. Morgan Stanley dropped their target price on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research report on Monday, October 20th. Finally, Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $77.44.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.